Search
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
FB-101
go.drugbank.com/drugs/DB17956InvestigationalDeveloped by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]
PS386113
go.drugbank.com/drugs/DB05211ExperimentalIt is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalOne of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).
ONO-2952
go.drugbank.com/drugs/DB14802InvestigationalONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable
Halofuginone
go.drugbank.com/drugs/DB04866InvestigationalVet approvedHalofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.
D-fluoromethyltyrosine F-18
go.drugbank.com/drugs/DB15296InvestigationalNCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small
AVAC
go.drugbank.com/drugs/DB05441Experimental[Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate